Trial reportPsychopharmacology2022
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
Trial report in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis.BMC psychology · 2026Pooled it
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- What interventions can improve social connections for military partners? A scoping review.Journal of military, veteran and family health · 2025Pooled it
- Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026Trial
- Trial
- Oxytocin Amplifies Negative Response to Ambiguity in Adolescent Females With and Without Eating Disorders.European eating disorders review : the journal of the Eating Disorders Association · 2025Trial
- Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.Molecular psychiatry · 2025Trial
- Psychedelics and the 'inner healer': Myth or mechanism?Journal of psychopharmacology (Oxford, England) · 2024Trial
- Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.Scientific reports · 2024Trial
- Psychedelic-assisted psychotherapy: Emerging paradigm.Canadian family physician Medecin de famille canadien · 2026Review
- Review
- Well-Being Elective in Health Professional Education: A Pilot Study.Pharmacy (Basel, Switzerland) · 2026Article
- Artificial Intelligence Connectedness: Theoretical Reconstruction of Connectedness and Its Impacts on Adolescent Mental Health.Behavioral sciences (Basel, Switzerland) · 2026Article
- Brain mechanisms supporting mindfulness-based chronic pain relief: A randomized, sham-mindfulness meditation controlled mechanistic clinical trial protocol.Contemporary clinical trials communications · 2026Article
- Exploring self-reported health behavior change following naturalistic psychedelic use.Journal of health psychology · 2026Article
- The mystic trip: how psychedelic research fell for mysticism.Psychopharmacology · 2026Review
- Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings.International journal of methods in psychiatric research · 2026Article
- Chaplains in Psychedelic Assisted Therapy: Rationale and Competencies.Journal of religion and health · 2026Article
- A Consensus Statement for Ecological Medicine: Moving Toward Connection-Based Medicine.EcoHealth · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleA general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of 'connectedness' as 'a state of feeling connected to self, others and the wider world'. Existing tools for measuring connectedness have focused on particular aspects of connectedness, such as 'social connectedness' or 'nature connectedness', which we hypothesise to be different expressions of a common factor of connectedness. Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains. We hypothesised that (1) our scale would measure three separable subscale factors pertaining to a felt connection to 'self', 'others' and 'world' and (2) improvements in total and subscale WCS scores would correlate with improved mental health outcomes post psychedelic use.
objectivesTo validate and test the 'Watts Connectedness Scale' (WCS).
methodsPsychometric validation of the WCS was carried out using data from three independent studies. Firstly, we pooled data from two prospective observational online survey studies. The WCS was completed before and after a planned psychedelic experience. The total sample of completers from the online surveys was N = 1226. Exploratory and confirmatory factor analysis were performed, and construct and criterion validity were tested. A third dataset was derived from a double-blind randomised controlled trial (RCT) comparing psilocybin-assisted therapy (n = 27) with 6 weeks of daily escitalopram (n = 25) for major depressive disorder (MDD), where the WCS was completed at baseline and at a 6-week primary endpoint.
resultsAs hypothesised, factor analysis of all WCS items revealed three main factors with good internal consistency. WCS showed good construct validity. Significant post-psychedelic increases were observed for total connectedness scores (η2 = 0.339, p < 0.0001), as well as on each of its subscales (p < 0.0001). Acute measures of 'mystical experience', 'emotional breakthrough', and 'communitas' correlated positively with post-psychedelic changes in connectedness (r = 0.42, r = 0.38, r = 0.42, respectively, p < 0.0001). In the RCT, psilocybin therapy was associated with greater increases in WCS scores compared with the escitalopram arm (η
conclusionsThe WCS is a new 3-dimensional index of felt connectedness that may sensitively measure therapeutically relevant psychological changes post-psychedelic use. We believe that the operational definition of connectedness captured by the WCS may have broad relevance in mental health research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.